The attenuated West Nile virus 25A strain (WN25A) was investigated for its neuroinvasive properties in B-cell-deficient (μMT) mice. After peripheral inoculation, WN25A caused fatal encephalitis in the majority of 6–8-week-old mice, characterized by a systemic infection with viraemia, moderate virus burdens in peripheral tissues and a high titre of brain-associated virus. Mice generally succumbed to infection within a few weeks of infection. However, others survived for as long as 10 weeks, and some for even longer. Normal age-matched C57BL/6 mice showed no signs of illness after inoculation with WN25A virus. Nucleotide sequencing of WN25A viruses recovered from the brains of B-cell-deficient mice revealed that the conserved N-linked glycosylation site in the viral envelope protein was abolished by substitution of a serine residue at position 155. This was found to be a pseudoreversion relative to the wild-type WN-Israel strain, based on virulence testing of one such brain-associated virus in both B-cell-deficient and normal C57BL/6 mice. This study provides further characterization of the mouse virulence properties of the attenuated WN25A virus in the context of B-cell deficiency. Replication in these mice does not involve rapid neuroadaptation or reversion of WN25A virus to a neuroinvasive phenotype. Molecular modelling studies suggest a difference in local structure of the E protein associated with either an asparagine or serine residue at position 155 compared with the tyrosine found in the virulent parental WN-Israel virus.
BeasleyD. W.,
LiL.,
SudermanM. T.,
BarrettA. D.2001; West Nile virus strains differ in mouse neurovirulence and binding to mouse or human brain membrane receptor preparations. Ann N Y Acad Sci 951:332–335
BeasleyD. W.,
LiL.,
SudermanM. T.,
BarrettA. D.2002; Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 296:17–23[CrossRef]
BeasleyD. W. C.,
WhitemanM. C.,
ZhangS.,
HuangC. Y.-H.,
SchneiderB. S.,
SmithD. R.,
GromowskiG. D.,
HiggsS.,
KinneyR. M.,
BarrettA. D. T.2005; Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol 79:8339–8347[CrossRef]
Ben-NathanD.,
LustigS.,
FeuersteinG.1989; The influence of cold or isolation stress on neuroinvasiveness and virulence of an attenuated variant of West Nile virus. Arch Virol 109:1–10[CrossRef]
Ben-NathanD.,
HuitingaI.,
LustigS.,
van RooijenN.,
KobilerD.1996; West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch Virol 141:459–469[CrossRef]
Ben-NathanD.,
LustigS.,
TamG.,
RobinzonS.,
SegalS.,
Rager-ZismanB.2003; Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 188:5–12[CrossRef]
BerthetF. X.,
ZellerH. G.,
DrouetM. T.,
RauzierJ.,
DigoutteJ. P.,
DeubelV.1997; Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses. J Gen Virol 78:2293–2297
BondreV. P.,
JadiR. S.,
MishraA. C.,
YergolkarP. N.,
ArankalleV. A.2007; West Nile virus isolates from India: evidence for a distinct genetic lineage. J Gen Virol 88:875–884[CrossRef]
BrandrissM. W.,
SchlesingerJ. J.,
WalshE. E.,
BriselliM.1986; Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 67:229–234[CrossRef]
BroomA. K.,
WallaceM. J.,
MackenzieJ. S.,
SmithD. W.,
HallR. A.2000; Immunisation with gamma globulin to Murray Valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against Australian encephalitis: evaluation in a mouse model. J Med Virol 61:259–265[CrossRef]
BurtF. J.,
GrobbelaarA. A.,
LemanP. A.,
AnthonyF. S.,
GibsonG. V.,
SwanepoelR.2002; Phylogenetic relationships of Southern African West Nile virus isolates. Emerg Infect Dis 8:820–826[CrossRef]
ChambersT. J.,
HalevyM.,
NestorowiczA.,
RiceC. M.,
LustigS.1998; West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness. J Gen Virol 79:2375–2380
DavisC. T.,
BeasleyD. W.,
GuzmanH.,
SiirinM.,
ParsonsR. E.,
TeshR. B.,
BarrettA. D.2004; Emergence of attenuated West Nile virus variants in Texas, 2003. Virology 330:342–350[CrossRef]
DiamondM. S.,
ShresthaB.,
MarriA.,
MahanD.,
EngleM.2003; B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77:2578–2586[CrossRef]
GoldblumN.,
StrekV. V.,
PaderskyB.1954; West Nile fever: the clinical features of the disease and isolation of West Nile from the blood of nine human cases. Am J Hyg 59:89–103
HalevyM.,
AkovY.,
Ben-NathanB.,
KobilerD.,
LachmiB.,
LustigS.1994; Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch Virol 137:355–370[CrossRef]
KatzY.,
LustigS.,
Ben-ShlomoI.,
KobilerD.,
Ben-NathanD.2002; Inhalation anesthetic-induced neuroinvasion by an attenuated strain of West Nile virus in mice. J Med Virol 66:576–580[CrossRef]
Kimura-KurodaJ.,
YasuiK.1988; Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 141:3606–3610
KobilerD.,
LustigS.,
GozesY.,
Ben-NathanD.,
AkovY.1989; Sodium dodecylsulphate induces a breach in the blood–brain barrier and enables a West Nile virus variant to penetrate into mouse brain. Brain Res 496:314–316[CrossRef]
LanciottiR. S.,
RoehrigJ. T.,
DeubelV.,
SmithJ.,
ParkerM.,
SteeleK.,
CriseB.,
VolpeK. E.,
CrabtreeM. B.other authors1999; Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286:2333–2337[CrossRef]
LeeE.,
HallR. A.,
LobigsM.2004; Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 78:8271–8280[CrossRef]
LustigS.,
DanenbergH. D.,
KafriY.,
KobilerD.,
Ben-NathanD.1992; Viral neuroinvasion and encephalitis induced by lipopolysaccharide and its mediators. J Exp Med 176:707–712[CrossRef]
LustigS.,
OlshevskyU.,
Ben-NathanD.,
LachmiB. E.,
MalkinsonM.,
KobilerD.,
HalevyM.2000; A live attenuated West Nile virus strain as a potential veterinary vaccine. Viral Immunol 13:401–410[CrossRef]
MathewsJ. H.,
RoehrigJ. T.1984; Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol 132:1533–1537
NybakkenG. E.,
NelsonC. A.,
ChenB. R.,
DiamondM. S.,
FremontD. H.2006; Crystal structure of the West Nile virus envelope glycoprotein. J Virol 80:11467–11474[CrossRef]
RappoleJ. H.,
DerricksonS. R.,
HubalekZ.2000; Migratory birds and spread of West Nile virus in the western hemisphere. Emerg Infect Dis 6:319–328[CrossRef]
RoehrigJ. T.,
StaudingerL. A.,
HuntA. R.,
MathewsJ. H.,
BlairC. D.2001; Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 951:286–297
RoehrigJ. T.,
LaytonM.,
SmithP.,
CampbellG. L.,
NasciR.,
LanciottiR. S.2002; The emergence of West Nile virus in North America: ecology, epidemiology, and surveillance. Curr Top Microbiol Immunol 267:223–240
ScherretJ. H.,
PoidingerM.,
MackenzieJ. S.,
BroomA. K.,
DeubelV.,
LipkinW. I.,
BrieseT.,
GouldE. A.,
HallR. A.2001; The relationships between West Nile and Kunjin viruses. Emerg Infect Dis 7:697–705[CrossRef]
ScherretJ. H.,
MackenzieJ. S.,
HallR. A.,
DeubelV.,
GouldE. A.2002; Phylogeny and molecular epidemiology of West Nile and Kunjin viruses. Curr Top Microbiol Immunol 267:373–390
SchlesingerJ. J.,
BrandrissM. W.,
WalshE. E.1985; Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol 135:2805–2809
ShiratoK.,
MiyoshiH.,
GotoA.,
AkoY.,
UekiT.,
KariwaH.,
TakashimaI.2004; Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J Gen Virol 85:3637–3645[CrossRef]
WenglerG.,
CastleE.,
LeidnerU.,
NowakT.,
WenglerG.1985; Sequence analysis of the membrane protein V3 of the flavivirus West Nile virus and of its gene. Virology 147:264–267[CrossRef]
YamshchikovV. F.,
WenglerG.,
PerelyginA. A.,
BrintonM. A.,
CompansR. W.2001; An infectious clone of the West Nile flavivirus. Virology 281:294–304[CrossRef]
YamshchikovG.,
BorisevichV.,
SereginA.,
ChaporginaE.,
MishinaM.,
MishinV.,
KwokC. W.,
YamshchikovV.2004; An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology 330:304–312[CrossRef]